Insulin Aspart: A New Rapid-Acting Insulin Analog
- 1 December 2000
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 34 (12) , 1423-1431
- https://doi.org/10.1345/aph.19414
Abstract
OBJECTIVE: To examine the pharmacology, therapeutics, pharmacokinetics, dosing guidelines, adverse effects, and drug interactions of insulin aspart, and summarize the clinical trials of efficacy and safety in patients with type 1 or type 2 diabetes mellitus. DATA SOURCES: A MEDLINE database search (1985–May 2000) was performed to identify all applicable published articles and abstracts; in some cases, Novo Nordisk unpublished information was also obtained. Review articles on insulin analogs were also identified, as well as review chapters in medical textbooks. STUDY SELECTION: The majority of the studies identified were in abstract form. These studies reported information on the pharmacokinetics of insulin aspart in healthy volunteers and in those with diabetes, as well as the therapeutic utility, safety, and clinical efficacy in patients with diabetes. A limited number of randomized studies were reported as articles in the medical literature. DATA EXTRACTION: All published clinical studies were reviewed. DATA SYNTHESIS: Insulin aspart, the second Food and Drug Administration—approved rapid-acting insulin analog, is produced by recombinant technology that replaces the proline at position 28 on the B chain of insulin with negatively charged aspartic acid. Insulin aspart exists as hexamers that rapidly dissociate into monomers and dimers on subcutaneous injection. When administered immediately prior to a meal, insulin aspart is at least as effective as regular human insulin in control of postprandial blood glucose concentrations. Insulin aspart achieves higher peak insulin concentrations in less time and with a shorter duration of action than regular human insulin. CONCLUSIONS: Insulin aspart is a convenient premeal insulin for use by patients requiring mealtime insulin. Furthermore, due to favorable pharmacokinetics, insulin aspart controls postprandial blood glucose concentrations at least as well as regular human insulin and contributes to improved quality of life.Keywords
This publication has 21 references indexed in Scilit:
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Interactions of Phenol and m-Cresol in the Insulin Hexamer, and Their Effect on the Association Properties of B28 Pro → Asp Insulin AnaloguesBiochemistry, 1998
- Fast-Acting Human Insulin Analogs: A Promising Innovation in Diabetes CareThe Diabetes Educator, 1995
- Effect of the Insulin Analogue [LYS(B28),PRO(B29)] on Blood Glucose ControlHormone and Metabolic Research, 1994
- Action Profile of the Rapid Acting Insulin Analogue: Human Insulin B28AspDiabetic Medicine, 1993
- The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptakeDiabetes/Metabolism Research and Reviews, 1992
- In Vitro and In Vivo Potency of Insulin Analogues Designed for Clinical UseDiabetic Medicine, 1991
- Absorption Kinetics and Action Profiles of Subcutaneously Administered Insulin Analogues (AspB9GluB27, AspB10, AspB28) in Healthy SubjectsDiabetes Care, 1991
- Comparison of Subcutaneous Soluble Human Insulin and Insulin Analogues (AspB9, GluB27; AspB10; AspB28) on Meal-Related Plasma Glucose Excursions in Type I Diabetic SubjectsDiabetes Care, 1991
- Monomeric Insulins and Their Experimental and Clinical ImplicationsDiabetes Care, 1990